太子健Ⅱ方对儿童哮喘慢性持续期免疫功能及气道慢性炎症的影响  

Effect of Chinese Medication on the Immune Function and Chronic Airway Inflammation in Asthma Children at Chronic Duration Stage

作　　者：李岚[1] 陈华[1] 陈健[1] 刘永林[1] 朱永琴[1] 任昱[1] 俞景茂[1] 

机构地区：[1]浙江中医药大学附属第一临床医学院,浙江省杭州市邮电路54号310006

出　　处：《中医杂志》2012年第23期2011-2013,2016,共4页Journal of Traditional Chinese Medicine

基　　金：浙江省中医药管理局基金资助项目(2011ZB044)

摘　　要：目的探讨太子健Ⅱ方治疗儿童哮喘慢性持续期的疗效及可能机制。方法将70例支气管哮喘患儿随机分为治疗组和对照组各35例。治疗组给予太子健Ⅱ方,每日1剂,分2次口服;对照组口服顺尔宁咀嚼片,每次5mg,每晚1次。均治疗3个月。观察两组患儿治疗前后哮喘发作次数、呼吸道感染次数、儿童哮喘控制测试(C-ACT)评分、尿白细胞三烯4(LTE4)及唾液分泌型免疫球蛋白A(sIgA)、中医证候积分变化及综合疗效。结果治疗组总有效率96.88%,对照组总有效率96.97%,两组比较差异无统计学意义(P>0.05)。治疗后治疗组中医证候积分显著下降,且优于对照组(P<0.01)。治疗后两组哮喘发作次数、尿LET4均显著下降(P<0.01),对照组尿LET4优于治疗组(P<0.01)。治疗后治疗组呼吸道感染次数显著减少(P<0.01),且优于对照组(P<0.05)。治疗后两组C-ACT评分、PEF%均显著升高(P<0.01)。治疗后治疗组唾液sIgA显著升高(P<0.01),且优于对照组(P<0.01)。结论太子健Ⅱ方能增强儿童哮喘慢性持续期患儿免疫功能及减轻气道慢性炎症,可作为儿童哮喘慢性持续期的治疗手段之一。Objective To observe the effect of Chinese medication on immune function and chronic airway inflammation in asthma children at chronic duration stage.Methods Seventy children with bronchial asthma at chronic duration stage were randomized into the treatment group and control group , with 35in each.The treatment group was given TaizijianⅡformula （ empirical formula of Prof.YU Jingmao ）, one dose daily , twice orally.The control group was given 5mg of singulair ,o nce every night.The treatment course lasted for 3months.The frequency of asthma attack and respiratory infection , child asthma control test （ C-ACT ）s cores, urine leukotriene E 4 （L TE 4 ）, salivary secretory immunoglobulin A （ sIgA ）, traditional Chinese medicine（ TCM） syndrome scores and comprehensive efficacy were observed and determined before and after treatment.Results The total effective rate of the treatment group and control group was 96.88%and 96.97%respectively , with no significant difference between groups （ P〈0.05 ） .There was no significant difference in TCM syndrome scores in the control group after treatment （ P〈0.05 ） .The TCM syndrome scores in the treatment group were significantly decreased after treatment （ P〈0.001 ）, with a significant difference between groups （ P〈0.001 ） .The frequency of asthma attack and the level of urine LTE 4 decreased significantly in both groups after treatment （ P〈0.01or P〈0.001 ）, with no significant difference between groups in the frequency of asthma attack （ P〈0.05 ）, but with a significant difference in the level of urine LTE 4 （ P〈0.01 ）. The frequency of respiratory infection decreased significantly in the treatment group after treatment （ P〈0.01 ）, with a significant difference between groups （ P〈0.05 ） .The C-ACT scores and peak expiratory flow （P EF） %increased significantly in both groups after treatment （ P〈0.001 ）, with no significant difference between groups （ P〈0.05 ） .The level of salivary sIgA

关 键 词：太子健Ⅱ方 支气管哮喘 慢性持续期 儿童 尿白细胞三烯4 唾液分泌型免疫球蛋白A 

分 类 号：R725.6[医药卫生—儿科]